The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Krysanov I.S.

Moscow State University of Food Production;
Institute of Cost-effectiveness Expertise and Pharmacoeconomics;
Russian University of Medicine

Makarova E.V.

Russian University of Medicine

Ermakova Yu.V.

Moscow State University of Food Production;
Institute of Cost-effectiveness Expertise and Pharmacoeconomics;
Sechenov First Moscow State Medical University

Kurkin D.V.

Russian University of Medicine

Vaskova L.B.

Sechenov First Moscow State Medical University

Cost-effectiveness analysis of triptorelin therapy for patients with prostate cancer in state healthcare system of the Russian Federation

Authors:

Krysanov I.S., Makarova E.V., Ermakova Yu.V., Kurkin D.V., Vaskova L.B.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2025;47(3): 83‑92

DOI: 10.17116/medtech20254703183

Read: 466 times

Buy for 300₽
Contact the author
Table of contents

COST-EFFECTIVENESS ANALYSIS OF TRIPTORELIN THERAPY FOR PATIENTS WITH PROSTATE CANCER IN STATE HEALTHCARE SYSTEM OF THE RUSSIAN FEDERATION
COST-EFFECTIVENESS ANALYSIS OF TRIPTORELIN THERAPY FOR PATIENTS WITH PROSTATE CANCER IN STATE HEALTHCARE SYSTEM OF THE RUSSIAN FEDERATION

To cite this article:

Krysanov IS, Makarova EV, Ermakova YuV, Kurkin DV, Vaskova LB. Cost-effectiveness analysis of triptorelin therapy for patients with prostate cancer in state healthcare system of the Russian Federation. Medical Technologies. Assessment and Choice. 2025;47(3):83‑92. (In Russ.)
https://doi.org/10.17116/medtech20254703183

Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Is arti­ficial inte­lligence nece­ssary for healthcare system?. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):40-48
Cost-effectiveness analysis of deno­sumab therapy in adults with solid tumors and bone meta­stases (in Russian healthcare). Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):74-89
Economic issues of medi­cal care for hype­rparathyroidism. Part 1. Primary hype­rparathyroidism. Medi­cal Technologies. Asse­ssment and Choice. 2025;(1):51-61
Cost-effectiveness analysis of bariatric surgery in obese patients. Medi­cal Technologies. Asse­ssment and Choice. 2025;(1):62-75
Pharmacoeconomic analysis of the neta­kimab use for the treatment of psoriasis vulgaris in the health care settings of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):99-105
Patterns of CAF expression in tumors of the geni­tourinary system. Russian Journal of Archive of Pathology. 2024;(6):28-35
Pote­ntial of specialized diet therapy in redu­cing toxic mani­festations in patients with meta­static castration-resistant prostate cancer with bone meta­stases during radionuclide therapy with radium chlo­ride [223Ra]. P.A. Herzen Journal of Onco­logy. 2024;(6):33-41
Post-exposure prophylaxis of influenza and ARVI. Resu­lts of a double-blind, placebo-controlled clinical trial of Meglumine acri­done acetate and its pharmacoeconomic rationale. Russian Journal of Preventive Medi­cine. 2025;(4):57-66
Remote resu­lts of treatment of patients with prostate cancer who unde­rwent radiation therapy in a combined version. P.A. Herzen Journal of Onco­logy. 2025;(3):14-19
Epidemiology and prevention of prostate cancer. Russian Journal of Preventive Medi­cine. 2025;(7):111-118
Abstract:

OBJECTIVE

Cost-effectiveness analysis of triptorelin and other luteinizing hormone releasing hormone (LHRH) agonists in the treatment of adults with prostate cancer.

MATERIAL AND METHODS

Cost-effectiveness analysis included costs of drugs and treatment of adverse events, budget impact analysis (BIA) and sensitivity analysis. Three LHRH agonists were selected (goserelin, leuprorelin, triptorelin).

RESULTS

The most efficient is triptorelin (35.870.01 rubles for a 9-month course of drug therapy). The highest cost is associated with leuprorelin therapy (54.945.51 rubles). Analysis of costs for AE relief showed that the lowest costs were associated with triptorelin (RUB 971.21), the highest — with goserelin (RUB 3.448.24). Thus, the highest total costs were associated with leuprorelin (RUB 57.857.15), the lowest — with triptorelin (RUB 36.841.22). The ratio of costs to probability of achieving serum testosterone<10 ng/dL after 9-month therapy was RUB 41.163.38 for triptorelin, RUB 69.456.36 for leuprorelin, and RUB 132.810.02 for goserelin. Triptorelin turned out to be strictly preferable compared to leuprorelin and goserelin due to higher efficiency and lower costs. According to BIA data, widespread triptorelin and leuprorelin therapy will decrease burden on healthcare system in the Russian Federation. Savings amount to 1 256 927.88 rubles for population of 1000 patients. Sensitivity analysis revealed that triptorelin retains its advantages even in deviations of baseline clinically significant parameters by ±10%.

CONCLUSION

Compared to other LHRH agonists, triptorelin is cost-effective strategy for care in patients with prostate cancer in the Russian Federation.

Keywords:

prostate cancer
goserelin
leuprorelin
triptorelin
cost-effectiveness analysis
budget impact analysis
pharmacoeconomy
LHRH agonists

Authors:

Krysanov I.S.

Moscow State University of Food Production;
Institute of Cost-effectiveness Expertise and Pharmacoeconomics;
Russian University of Medicine

Makarova E.V.

Russian University of Medicine

Ermakova Yu.V.

Moscow State University of Food Production;
Institute of Cost-effectiveness Expertise and Pharmacoeconomics;
Sechenov First Moscow State Medical University

Kurkin D.V.

Russian University of Medicine

Vaskova L.B.

Sechenov First Moscow State Medical University

Received:

22.05.2025

Accepted:

24.06.2025

Close metadata

References:

  1. Klinicheskie rekomendacii. Rak predstatel`noj zhelezy`. 2021. Accessed July 12,2025. (In Russ.). https://oncology-association.ru/wp-content/uploads/2021/02/rpzh.pdf
  2. Nosov DA, Volkova MI, Gladkov OA, Karabina EV, Kry`lov VV, Matveev VB, et al. Rak predstatel`noj zhelezy`. Prakticheskie rekomendacii RUSSCO, chast` 1,2. Zlokachestvenny`e opuxoli. 2024;14(3s2-2):242-266. (In Russ.). https://doi.org/10.18027/2224-5057-2024-14-3s2-1.2-10
  3. Cornford P, van den Bergh RCN, Briers E, van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer — 2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent Cornford. European Urology. 2024;86(2):148-163.  https://doi.org/10.1016/j.eururo.2024.03.027
  4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-249.  https://doi.org/10.3322/caac.21660
  5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: A Cancer Journal for Clinicians. 2020;70:7-30.  https://doi.org/10.3322/CAAC.21590
  6. Stewart RW, Lizama S, Peairs K, Sateia HF, Choi Y. Screening for prostate cancer. Seminars in Oncology. 2017;44:47-56.  https://doi.org/10.1053/j.seminoncol.2017.02.001
  7. Sostojanie onkologicheskoj pomoshhi naseleniju Rossii v 2023 godu. Pod red. Kaprina AD, Starinskogo VV, Shahzadovoj AOM.: MNIOI im. PA. Gercena — filial FGBU «NMIC radiologii» MinzdravaRossii; 2024. (In Russ.).
  8. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA: A Cancer Journal for Clinicians. 1972;22:293-297.  https://doi.org/10.3322/canjclin.22.4.232
  9. Alekseyev BYa, Nyushko KM. Hormonal therapy for prostate cancer. Onkourologiya. 2007;3(3):57-62. (In Russ.).
  10. Matveev VB, Alekseev BYa, Kamolov BSh, Markova AS. Luteinizing hormone-releasing hormone agonists for prostate cancer patients: routine clinical practice of Russian cancer urologists. Onkourologiya. 2021;17(2):83-92. (In Russ.). https://doi.org/10.17650/1726-9776-2021-17-2-83-92
  11. Metodicheskie rekomendacii po provedeniyu sravnitel`noj kliniko-e`konomicheskoj ocenki lekarstvennogo preparata (novaya redakciya). FGBU «Centr ekspertizy i kontrolya kachestva medicinskoj pomoshchi» Ministerstva zdravoohraneniya Rossijskoj Federacii. M, 2018. (In Russ.).
  12. Metodicheskie rekomendacii po ispol`zovaniyu matematicheskogo modelirovaniya v kliniko-e`konomicheskix issledovaniyax i issledovaniyax s ispol`zovaniem analiza vliyaniya na byudzhet. FGBU «Centr ekspertizy i kontrolya kachestva medicinskoj pomoshchi» Ministerstva zdravoohraneniya Rossijskoj Federacii. M, 2019. (In Russ.).
  13. Vorob`ev PA, Avksent`eva MV, Borisenko OV. Kliniko-e`konomicheskij analiz. 3rd ed. M.: N`YUDIAMED; 2008.
  14. Breul J, Lundström E, Purcea D, Venetz WP, Cabri P, Dutailly P, Goldfischer ER. Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer. Advances in Therapy. 2017;34(2):513-523.  https://doi.org/10.1007/s12325-016-0466-7
  15. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology. 2000;56(6):1021-1024. https://doi.org/10.1016/s0090-4295(00)00793-7
  16. Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. Journal of Urology. 2007;178(4 Pt 1):1290-1295. https://doi.org/10.1016/j.juro.2007.05.129
  17. Dason S, Allard CB, Tong J, Shayegan B. Defining a new testosterone threshold for medical castration: Results from a prospective cohort series. Canadian Urological Association Journal. 2013;7(5-6):E263-267.  https://doi.org/10.5489/cuaj.471
  18. Klotz L, O’Callaghan C, Ding K, Toren P, Dearnaley D, Higano CS, et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. Journal of Clinical Oncology. 2015;33(10):1151-1156. https://doi.org/10.1200/JCO.2014.58.2973
  19. Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU International. 2010;105(5):648-651.  https://doi.org/10.1111/j.1464-410X.2009.08814.x
  20. Reis LO, Denardi F, Faria EF, Silva ED. Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated with Diverse Chemical Castrations. American Journal of Men’s Health. 2015;9(5):430-434.  https://doi.org/10.1177/1557988314552468
  21. Kamada S, Sakamoto S, Ando K, Muroi A, Fuse M, Kawamura K, et al. Nadir Testosterone after Long-Term Followup Predicts Prognosis in Patients with Prostate Cancer Treated with Combined Androgen Blockade. Journal of Urology. 2015;194(5):1264-1270. https://doi.org/10.1016/j.juro.2015.03.120
  22. Klotz L, Tat T. Testosterone nadir and clinical outcomes in patients with advanced prostate cancer: Post hoc analysis of triptorelin pamoate Phase III studies. BJUI Compass. 2024;5(3):392-402.  https://doi.org/10.1002/bco2.318
  23. Shim M, Bang WJ, Oh CY, Lee YS, Cho JS. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide. Investigative and Clinical Urology. 2019;60:244.  https://doi.org/10.4111/ICU.2019.60.4.244
  24. Metodicheskie rekomendacii po ocenke vliyaniya na byudzhet v ramkax realizacii programmy` gosudarstvenny`x garantiǐ besplatnogo okazaniya grazhdanam medicinskoǐ pomoshhi. FGBU «Centr ekspertizy i kontrolya kachestva medicinskoj pomoshchi» Ministerstva zdravoohraneniya Rossijskoj Federacii. M, 2018. (In Russ.).
  25. Novara G, Galfano A, Secco S, Ficarra V, Artibani W. Impact of surgical and medical castration on serum testosterone level in prostate cancer patients. Urologia Internationalis. 2009;82(3):249-255.  https://doi.org/10.1159/000209352
  26. Hupe MC, Hammerer P, Ketz M, Kossack N, Colling C, Merseburger AS. Retrospective SHI (Statutory Health Insurances) real-world study on initial GnRH antagonist and agonist therapy for advanced prostate cancer: prescription patterns and hospital costs in Germany]. Aktuelle Urology. 2020;51(3):275-284.  https://doi.org/10.1055/a-1018-1651
  27. Poliakova KI, Holownia-Voloskova ME, Byakhov MYu, Ermolaeva TN, Fisun AG, Dubovtseva VA, et al. Comparative Analysis Of Cost Of Drug Therapy Of The Most High-Cost Oncological Diseases In Moscow. Zlokachestvenny`e opuxoli. 2018;8(2):12-20. (In Russ.). https://doi.org/10.18027/2224-5057-2018-8-2-12-20
  28. Polyakova KI, Fisun AG, Govorov AV, Krysanova VS, Andreev DA, Ermolaeva TN, et al. Modern drug therapy of prostate cancer through the example of Moscow. Onkourologiya. 2019;15(2):77-85. (In Russ.). https://doi.org/10.17650/1726-9776-2019-15-2-77-85
  29. Frolov MYu, Avksentyeva MV. Pharmacoeconomic analysis of leuprolide acetate (Eligard) 45 mg once in 6 months for advanced prostate cancer In Russian Federation. Onkourologiya. 2015;11(4):65-71. (In Russ.). https://doi.org/10.17650/1726-9776-2015-11-4-65-71
  30. Tolkushin AG, Pogudina NL. Pharmacoeconomic study of the degarelix drug use for treatment of hormone-dependent prostate cancer compared to gonadotropin-releasing hormone analogs. Onkourologiya. 2018;14(1):126-135. (In Russ.). https://doi.org/10.17650/1726-9776-2018-14-1-126-135
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.